复发性生殖器疱疹的单纯疱疹病毒糖蛋白免疫疗法：影响疗效的因素

Herpes simplex virus glycoprotein immunotherapy of recurrent genital herpes: factors influencing efficacy.

作者信息

Stanberry L R, Harrison C J, Bernstein D I, Burke R L, Shukla R, Ott G, Myers M G

机构信息

Division of Infectious Diseases, Children's Hospital Research Foundation, Cincinnati, Ohio 45229-2899.

出版信息

Antiviral Res. 1989 May-Jun;11(4):203-14. doi: 10.1016/0166-3542(89)90005-3.

DOI:10.1016/0166-3542(89)90005-3

PMID:2545166

Abstract

Recombinant herpes simplex virus type 1 (HSV-1) glycoproteins B (gB) and D (gD) were used as immunotherapeutic agents for the treatment of recurrent genital herpes in guinea pigs. Administration of a gBgD vaccine eight to 21 days after intravaginal HSV-2 inoculation significantly increased the titer of anti-HSV antibodies (P less than 0.005) while significantly reducing the frequency of subsequent herpetic recurrences (P less than 0.05). The effectiveness of gBgD immunotherapy was influenced by both the co-administration of adjuvant, the type of adjuvant, and by the timing and route of administration. These data demonstrate that recurrent HSV disease in animals with established latent infection may be favorably altered by the administration of immunogenic viral proteins.

摘要

重组单纯疱疹病毒1型（HSV-1）糖蛋白B（gB）和糖蛋白D（gD）被用作免疫治疗剂，用于治疗豚鼠复发性生殖器疱疹。在阴道内接种HSV-2后8至21天给予gBgD疫苗，可显著提高抗HSV抗体滴度（P<0.005），同时显著降低随后疱疹复发的频率（P<0.05）。gBgD免疫疗法的有效性受佐剂的共同给药、佐剂类型以及给药时间和途径的影响。这些数据表明，给予免疫原性病毒蛋白可能会有利地改变已建立潜伏感染动物的复发性HSV疾病。